CN1244589C - 腺苷a3受体激动剂 - Google Patents

腺苷a3受体激动剂 Download PDF

Info

Publication number
CN1244589C
CN1244589C CNB02815486XA CN02815486A CN1244589C CN 1244589 C CN1244589 C CN 1244589C CN B02815486X A CNB02815486X A CN B02815486XA CN 02815486 A CN02815486 A CN 02815486A CN 1244589 C CN1244589 C CN 1244589C
Authority
CN
China
Prior art keywords
optionally substituted
compound
formula
hydroxymethyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB02815486XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1538972A (zh
Inventor
埃尔法蒂赫·埃尔扎因
文卡塔·帕勒
维布哈夫·瓦尔凯赫特卡
杰夫·扎布沃茨基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of CN1538972A publication Critical patent/CN1538972A/zh
Application granted granted Critical
Publication of CN1244589C publication Critical patent/CN1244589C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CNB02815486XA 2001-08-08 2002-08-06 腺苷a3受体激动剂 Expired - Fee Related CN1244589C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31106901P 2001-08-08 2001-08-08
US60/311,069 2001-08-08

Publications (2)

Publication Number Publication Date
CN1538972A CN1538972A (zh) 2004-10-20
CN1244589C true CN1244589C (zh) 2006-03-08

Family

ID=23205248

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB02815486XA Expired - Fee Related CN1244589C (zh) 2001-08-08 2002-08-06 腺苷a3受体激动剂

Country Status (20)

Country Link
US (1) US20030078232A1 (cg-RX-API-DMAC7.html)
EP (1) EP1414837B1 (cg-RX-API-DMAC7.html)
JP (1) JP4357960B2 (cg-RX-API-DMAC7.html)
KR (1) KR100923888B1 (cg-RX-API-DMAC7.html)
CN (1) CN1244589C (cg-RX-API-DMAC7.html)
AT (1) ATE307136T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002327426C1 (cg-RX-API-DMAC7.html)
CA (1) CA2456744A1 (cg-RX-API-DMAC7.html)
DE (1) DE60206775T2 (cg-RX-API-DMAC7.html)
DK (1) DK1414837T3 (cg-RX-API-DMAC7.html)
ES (1) ES2247371T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0401437A3 (cg-RX-API-DMAC7.html)
IL (2) IL160231A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04001185A (cg-RX-API-DMAC7.html)
NO (1) NO327997B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ530976A (cg-RX-API-DMAC7.html)
PL (1) PL368205A1 (cg-RX-API-DMAC7.html)
RU (1) RU2298557C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003014137A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200401000B (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
EP2048142A3 (en) * 2001-04-26 2009-04-22 Eisai R&D Management Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US6914053B2 (en) * 2002-09-09 2005-07-05 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
NZ585697A (en) 2004-08-02 2011-12-22 Univ Virginia Patent Found 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
CN101083998A (zh) * 2004-11-22 2007-12-05 王者制药研究发展有限公司 用腺苷a3受体激动剂强化治疗hif-1介导的病症
EP1845973B1 (en) 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
US7381714B2 (en) * 2005-05-19 2008-06-03 Cv Therapeutics, Inc. A1 adenosine receptor agonists
US7514417B2 (en) 2005-05-19 2009-04-07 Cv Therapeutics, Inc. A1 adenosine receptor agonists
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7488720B2 (en) 2005-10-13 2009-02-10 Cv Therapeutics, Inc. A1 adenosine receptor agonists
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
JP5703432B2 (ja) * 2007-03-28 2015-04-22 ノイロサーチ アクティーゼルスカブ プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
EP2142546B1 (en) 2007-03-28 2017-06-07 Saniona A/S Purinyl derivatives and their use as potassium channel modulators
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
JP2011500716A (ja) * 2007-10-16 2011-01-06 ギリアード・パロ・アルト・インコーポレイテッド A3アデノシン受容体アンタゴニスト
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
RU2451010C1 (ru) * 2011-01-11 2012-05-20 Закрытое Акционерное Общество "Ива Фарм" Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия
EP2885290B1 (en) 2012-06-26 2017-10-18 Saniona A/S A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
CN120647702A (zh) * 2017-05-19 2025-09-16 全技术公司 药剂、组合物及其相关方法
ES3070946T3 (en) 2019-03-12 2026-06-18 Arcus Biosciences Inc Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
US20220332750A1 (en) * 2019-06-21 2022-10-20 Academy Of Military Medical Sciences Adenosine compound, its pharmaceutically acceptable salt or its stereoisomer and use thereof
JP2024502068A (ja) * 2020-12-29 2024-01-17 チョーチヤン ビムグリーン ファーマシューティカルズ、リミテッド A3アデノシン受容体アゴニスト及びその調製方法と用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6180615B1 (en) * 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists

Also Published As

Publication number Publication date
EP1414837A1 (en) 2004-05-06
AU2002327426C1 (en) 2008-03-06
KR100923888B1 (ko) 2009-10-28
HUP0401437A2 (hu) 2004-11-29
JP4357960B2 (ja) 2009-11-04
AU2002327426A2 (en) 2003-02-24
PL368205A1 (en) 2005-03-21
DE60206775D1 (de) 2006-03-02
RU2004106635A (ru) 2005-07-27
EP1414837B1 (en) 2005-10-19
RU2298557C2 (ru) 2007-05-10
ZA200401000B (en) 2004-10-18
NO20040969L (no) 2004-04-19
US20030078232A1 (en) 2003-04-24
IL160231A0 (en) 2004-07-25
IL160231A (en) 2010-11-30
NO327997B1 (no) 2009-11-09
DE60206775T2 (de) 2006-07-20
CN1538972A (zh) 2004-10-20
KR20040023733A (ko) 2004-03-18
HUP0401437A3 (en) 2007-05-29
WO2003014137A1 (en) 2003-02-20
NZ530976A (en) 2005-07-29
ES2247371T3 (es) 2006-03-01
DK1414837T3 (da) 2005-11-07
CA2456744A1 (en) 2003-02-20
AU2002327426B2 (en) 2007-06-14
ATE307136T1 (de) 2005-11-15
MXPA04001185A (es) 2005-06-17
JP2005501842A (ja) 2005-01-20

Similar Documents

Publication Publication Date Title
CN1538972A (zh) 腺苷a3受体激动剂
CN1154494C (zh) 腺苷a3受体调节剂
CN1636009A (zh) A1 腺苷受体的部分和全促效药
CN1882588A (zh) A2b腺苷受体拮抗剂
CN1585769A (zh) A2b腺苷受体拮抗剂
CN1128149C (zh) 6,9-二取代的2-[反-(4-氨基环己基)氨基]嘌呤
CN1856496A (zh) 抑制hiv复制的嘌呤衍生物
CN1324025C (zh) 作为ccr5调节剂的托烷衍生物
CN1890241A (zh) A2b腺苷受体拮抗剂
CN1400975A (zh) 嘌呤衍生物
CN1946405A (zh) 9h-嘌呤-2,6-二胺衍生物在治疗增殖性疾病中的应用以及新的9h-嘌呤-2,6-二胺衍生物
CN101039677A (zh) 利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法
CN101031569A (zh) 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
CN101068825A (zh) 具有a2a激动剂活性的具有修饰的5'-核糖基团的2-丙炔基腺苷类似物
CN1422273A (zh) 1,5-二取代-3,4-二氢-1H-嘧啶并[4,5-d]嘧啶二酮化合物和其在治疗CSBP/p38激酶介导的疾病中的用途
CN1379777A (zh) 氨基-三唑并吡啶衍生物
CN1668610A (zh) 苯基-[4-(3-苯基-1h-吡唑-4-基)-嘧啶-2-基]-胺衍生物
CN1478085A (zh) 用于治疗冠状动脉疾病或动脉粥样硬化的abca-1提高化合物
CN1541215A (zh) 抑制hiv的嘧啶衍生物
CN1119440A (zh) 2,6-二氨基嘌呤衍生物
CN1432020A (zh) 嘌呤衍生物
CN1816549A (zh) 磷脂酰肌醇3-激酶抑制剂
CN1342145A (zh) 稠环化合物及其药物用途
CN101048410A (zh) 抑制hiv的双环嘧啶衍生物
CN1751030A (zh) 抑制hiv复制的嘧啶和三嗪

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: GILEAD PALO ALTO CO., LTD.

Free format text: FORMER OWNER: CV PHARMACEUTICAL CO., LTD.

Effective date: 20100519

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20100519

Address after: American California

Patentee after: Cv Therapeutics Inc.

Address before: American California

Patentee before: CV Therapeutics Inc.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060308

Termination date: 20100806